Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Health-care companies rose slightly as traders bought into defensive sectors in light of uncertainty about tariff levels.

Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when prescribed for other medical conditions. Exception requests from doctors may provide ...

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

The late Dr Michael Mosley was the nation’s trusted authority on how to improve our health. Now his son Jack is continuing ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...

Can you get addicted to weight loss? You most certainly can - and recently, colleagues and I have noticed a surge in patients ...